Literature DB >> 28752347

[Prolonged neuroleptic malignant syndrome after Haloperidol injection].

N Wystub1, S Heymel2, M Fritzenwanger2, P C Schulze2, R Pfeifer2.   

Abstract

Neuroleptic malignant syndrome (NMS) is a rare disorder caused by drug-induced dopamine-receptor-blockage or low dopamine concentration in the brain. It is a severe reaction to neuroleptic drugs in antipsychotic therapy. Symptoms in NMS typically consist of fever, muscle rigidity and cognitive changes; laboratory findings include elevated infectious disease markers and creatine kinase as well as signs of rhabdomyolysis. To differentiate NMS from other malignant hyperthermia syndromes identifying the offending drug and clinical history are essential. Therapy in NMS includes withdrawal of the causative medication and intensive care treatment possibly with administration of dantrolene.In this case report, we describe the clinical course of a 48 year old man who developed typical clinical symptoms and laboratory parameters of malignant hyperthermia syndrome after injection of haloperidol.

Entities:  

Keywords:  Fever; Malignant hyperthermia; Neuroleptic drugs; Neuroleptic malignant syndrome; Rhabdomyolysis

Mesh:

Substances:

Year:  2017        PMID: 28752347     DOI: 10.1007/s00063-017-0325-6

Source DB:  PubMed          Journal:  Med Klin Intensivmed Notfmed        ISSN: 2193-6218            Impact factor:   0.840


  18 in total

Review 1.  Neuroleptic malignant syndrome.

Authors:  P Adnet; P Lestavel; R Krivosic-Horber
Journal:  Br J Anaesth       Date:  2000-07       Impact factor: 9.166

2.  Fatal hyperpyrexia during chlorpromazine therapy.

Authors:  F J AYD
Journal:  J Clin Exp Psychopathol       Date:  1956 Apr-Jun

Review 3.  [Malignant hyperthermia syndrome in the intensive care unit : Differential diagnosis and acute measures].

Authors:  W Grander
Journal:  Med Klin Intensivmed Notfmed       Date:  2016-06-07       Impact factor: 0.840

4.  Neuroleptic malignant syndrome induced by a single injection of haloperidol.

Authors:  F Konikoff; A Kuritzky; Y Jerushalmi; E Theodor
Journal:  Br Med J (Clin Res Ed)       Date:  1984-11-03

5.  Neuroleptic malignant syndrome after the use of venlafaxine in a patient with generalized anxiety disorder.

Authors:  Tsung-Chien Lu; Pei-Lun Chu; Chi-Shin Wu; Kuang-Chau Tsai; Wen-Jone Chen
Journal:  J Formos Med Assoc       Date:  2006-01       Impact factor: 3.282

Review 6.  Mortality from neuroleptic malignant syndrome.

Authors:  A Shalev; H Hermesh; H Munitz
Journal:  J Clin Psychiatry       Date:  1989-01       Impact factor: 4.384

7.  A case of neuroleptic malignant syndrome successfully treated with amantadine.

Authors:  M M McCarron; M L Boettger; J J Peck
Journal:  J Clin Psychiatry       Date:  1982-09       Impact factor: 4.384

8.  Olanzapine-Induced Malignant Neuroleptic Syndrome.

Authors:  Tuba Berra Sarıtaş; Barış Çankaya; Alper Yosunkaya
Journal:  Turk J Anaesthesiol Reanim       Date:  2014-07-09

Review 9.  Update on procalcitonin measurements.

Authors:  Michael Meisner
Journal:  Ann Lab Med       Date:  2014-06-19       Impact factor: 3.464

10.  Extreme Procalcitonin Elevation without Proven Bacterial Infection Related to Amphetamine Abuse.

Authors:  András Lovas; Zsuzsanna Agoston; Klára Késmárky; Péter Hankovszky; Zsolt Molnár
Journal:  Case Rep Crit Care       Date:  2014-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.